(Q37960812)

26 August 2017

title

Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease (English)

1 reference

26 August 2017

main subject

cardiovascular disease

1 reference

Ahmed A Elmarakby

1

1 reference

26 August 2017

publication date

23 November 2011

1 reference

American Journal of Physiology - Regulatory, Integrative and Comparative Physiology

26 August 2017

published in

1 reference

26 August 2017

volume

302

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

R321-30

1 reference

Heme oxygenase: the key to renal function regulation

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK(Ca) channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Epoxyeicosatrienoic acid prevents postischemic electrocardiogram abnormalities in an isolated heart model

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Cardioprotective effect of a dual acting epoxyeicosatrienoic acid analogue towards ischaemia reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

The CYP2J2 G-50T polymorphism and myocardial infarction in patients with cardiovascular risk profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Genetic analysis of the soluble epoxide hydrolase gene, EPHX2, in subclinical cardiovascular disease in the Diabetes Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Inhibition of soluble epoxide hydrolase by trans-4- [4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

An essential role for SRC-activated STAT-3 in 14,15-EET-induced VEGF expression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Altered soluble epoxide hydrolase gene expression and function and vascular disease risk in the stroke-prone spontaneously hypertensive rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Induction of heme oxygenase-1 in vivo suppresses NADPH oxidase derived oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Altered kidney CYP2C and cyclooxygenase-2 levels are associated with obesity-related albuminuria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Protective effects of epoxyeicosatrienoic acids on human endothelial cells from the pulmonary and coronary vasculature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Multiple antiapoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Lifetime costs of medical care after heart failure diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

TNF-alpha inhibition reduces renal injury in DOCA-salt hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Chemokine receptor 2b inhibition provides renal protection in angiotensin II - salt hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Opposite regulation of cholesterol levels by the phosphatase and hydrolase domains of soluble epoxide hydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

11,12-epoxyeicosatrienoic acid (11,12-EET): structural determinants for inhibition of TNF-alpha-induced VCAM-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Activation of peroxisome proliferator-activated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

IP3 sensitizes TRPV4 channel to the mechano- and osmotransducing messenger 5'-6'-epoxyeicosatrienoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Cytochrome P450 2C is an EDHF synthase in coronary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Epoxyeicosatrienoic acids, cell signaling and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Mechanism of action of cerebral epoxyeicosatrienoic acids on cerebral arterial smooth muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Peroxisome proliferator-activated receptor {alpha} agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Association between myocardial infarction and fractures: an emerging phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

PPARalpha agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Afferent arteriolar dilation to 11, 12-EET analogs involves PP2A activity and Ca2+-activated K+ Channels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Development of epoxyeicosatrienoic acid analogs with in vivo anti-hypertensive actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Epoxyeicosatrienoic acid agonist regulates human mesenchymal stem cell-derived adipocytes through activation of HO-1-pAKT signaling and a decrease in PPARγ

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Soluble epoxide hydrolase in the generation and maintenance of high blood pressure in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Membrane-potential-dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Role of ADP-ribose in 11,12-EET-induced activation of K(Ca) channels in coronary arterial smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET)

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Gerry Brooks and epoxide hydrolases: four decades to a pharmaceutical

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP-9 via inhibition of NF-kappabeta in hyperhomocysteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Epoxide hydrolases: their roles and interactions with lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Role of EDHF in type 2 diabetes-induced endothelial dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

11,12-Epoxyeicosatrienoic acid-induced inhibition of FOXO factors promotes endothelial proliferation by down-regulating p27Kip1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Cytochrome P450 2C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Polymorphisms in human soluble epoxide hydrolase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Pathogenic perspectives for the role of inflammation in diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Heart disease and stroke statistics--2011 update: a report from the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

PPARs and the kidney in metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Role of cytochrome P450 metabolites of arachidonic acid in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Soluble epoxide hydrolase is a therapeutic target for acute inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

8,9-Epoxyeicosatrienoic acid protects the glomerular filtration barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Soluble epoxide hydrolase inhibition modulates vascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Arachidonic acid cytochrome P450 epoxygenase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Role of cytochrome P-450 metabolites in the regulation of renal function and blood pressure in 2-kidney 1-clip hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Alteration in endothelial function and modulation by treatment with pioglitazone in rabbit renal artery from short-term hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Physiology and pathophysiology of heme: implications for kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Crosstalk between EET and HO-1 downregulates Bach1 and adipogenic marker expression in mesenchymal stem cell derived adipocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Modulation of the Ca2 permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Intrarenal cytochrome P-450 metabolites of arachidonic acid in the regulation of the nonclipped kidney function in two-kidney, one-clip Goldblatt hypertensive rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Downregulation of renal CYP-derived eicosanoid synthesis in rats with diet-induced hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

20-hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Increased CYP2J3 expression reduces insulin resistance in fructose-treated rats and db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Cardiovascular disease in recent onset diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Activation of sphingosine kinase-1 mediates induction of endothelial cell proliferation and angiogenesis by epoxyeicosatrienoic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Cytochrome P-450 epoxygenases protect endothelial cells from apoptosis induced by tumor necrosis factor-alpha via MAPK and PI3K/Akt signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Fibroblast growth factor-2 is a downstream mediator of phosphatidylinositol 3-kinase-Akt signaling in 14,15-epoxyeicosatrienoic acid-induced angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Soluble epoxide hydrolase: a novel therapeutic target in stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

Decreased renal cytochrome P450 2C enzymes and impaired vasodilation are associated with angiotensin salt-sensitive hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPREGU.00606.2011

10.1152/AJPREGU.00606.2011

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference